1. Pink Sheet
  2. >>Regulatory Trackers

COVID-19 Vaccine Refresh For Boosters Only? US FDA Position On Primary Series May Have Shifted

 
• By Sarah Karlin-Smith

FDA advisors will vote 28 June on whether an Omicron component should be included in new COVID-19 booster vaccines. Following WHO recommendations, the FDA may no longer also be looking to update the primary vaccine series at this time. 

car gear stick
VRBPAC preview documents indicate FDA may no longer be committed to updating primary vaccine series at same time as boosters. • Source: Shutterstock

The US Food and Drug Administration appears to be focused on updating COVID-19 vaccine boosters for the fall while leaving the original primary vaccination series in place, briefing documents released ahead of a 28 June Vaccines and Related Biological Products Advisory Committee indicate.

This position would represent a shift in thinking from the agency’s comments in April, when it said it wanted to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

EU Authorization Before US? Biologics Manufacturing Is Likely To Blame

 
• By Bridget Silverman

In the infrequent cases when EU authorization precedes US FDA approvals of new products, biologics manufacturing issues are usually to blame, a Pink Sheet analysis found.

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.